[Changes in the sale and use of flunitrazepam in Norway after 1999]
- PMID:16505866
[Changes in the sale and use of flunitrazepam in Norway after 1999]
Abstract
Background: In Norway there has in later years been much discussion of misuse of flunitrazepam. From 1 January 2003 the drug was moved up one level in the schedule of controlled substances. On 1 August 2004 the manufacturer of the Rohypnol brand withdrew it from the Norwegian market. How did these two events influence the sales and use of drugs containing flunitrazepam?
Materials and methods: Sales figures for drugs containing flunitrazepam from the statistics database at the Norwegian Institute of Public Health were studied. The Norwegian prescription database was used to describe new (incident) users of flunitrazepam and the two brands of this drug sold in Norway in 2004.
Results and discussion: Restrictions on the prescription status of flunitrazepam lead to a decrease in sales from 7.2 defined daily doses (DDD) per 1000 inhabitants per day in 2002 to 3.0 DDD per 1000 inhabitants per day in 2003. This decrease was only partly compensated for by an increase in the sales of nitrazepam (from 5.0 to 6.0 DDD per 1000 inhabitants per day). During the years 1999 to 2004 there was a steady increase in the sales of benzodiazepine-related hypnotics (zopiclone and zolpidem). This shift could mean a change from flunitrazepam to zopiclone. The withdrawal of Rohypnol in August 2004 had only minor effects on the total sales of flunitrazepam. The decline in sales of Rohypnol was almost compensated for by the increase in the overall sales of Flunipam. This was reflected in the fact that in the later months of 2004 there were many new (incident) users of Flunipam, but few new users of flunitrazepam-containing drugs in total. It could be concluded that the restrictions on prescription status of flunitrazepam had a much higher impact than the withdrawal of the Rohypnol brand.
Similar articles
- Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam.Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J.Gustavsen I, et al.Sleep Med. 2008 Dec;9(8):818-22. doi: 10.1016/j.sleep.2007.11.011. Epub 2008 Jan 28.Sleep Med. 2008.PMID:18226959
- [Control of medical practitioners' prescription of flunitrazepam preparations in the County of Copenhagen and municipality of Frederiksberg].Hoffmeyer JH, Klebak S, Osler M.Hoffmeyer JH, et al.Ugeskr Laeger. 1999 Sep 27;161(39):5429-32.Ugeskr Laeger. 1999.PMID:10553356Danish.
- [Antibiotic use in Norway].Litleskare I, Blix HS, Rønning M.Litleskare I, et al.Tidsskr Nor Laegeforen. 2008 Oct 23;128(20):2324-9.Tidsskr Nor Laegeforen. 2008.PMID:19096488Norwegian.
- [The pharmacology of flunitrazepam (provided under the trade name Rohypnol)].Kapp W.Kapp W.Klin Anasthesiol Intensivther. 1978;(17):1-7.Klin Anasthesiol Intensivther. 1978.PMID:28431Review.German.No abstract available.
- Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries.Wirtz VJ, Herrera-Patino JJ, Santa-Ana-Tellez Y, Dreser A, Elseviers M, Vander Stichele RH.Wirtz VJ, et al.Trop Med Int Health. 2013 Jun;18(6):665-73. doi: 10.1111/tmi.12096. Epub 2013 Mar 29.Trop Med Int Health. 2013.PMID:23551290Review.
Cited by
- Lormetazepam addiction: data analysis from an Italian medical unit for addiction.Faccini M, Leone R, Pajusco B, Quaglio G, Casari R, Albiero A, Donati M, Lugoboni F.Faccini M, et al.Risk Manag Healthc Policy. 2012;5:43-8. doi: 10.2147/RMHP.S31745. Epub 2012 Jun 12.Risk Manag Healthc Policy. 2012.PMID:22792010Free PMC article.
- High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde.Faccini M, Tamburin S, Casari R, Morbioli L, Lugoboni F.Faccini M, et al.Intern Emerg Med. 2019 Nov;14(8):1271-1278. doi: 10.1007/s11739-019-02101-8. Epub 2019 May 10.Intern Emerg Med. 2019.PMID:31076977
- Regulatory Framework Implementation for the Prescription of Zolpidem in France, What Impact in the Older People?Jobert A, Istvan M, Laforgue EJ, Schreck B, Victorri-Vigneau C.Jobert A, et al.Int J Environ Res Public Health. 2021 Nov 18;18(22):12099. doi: 10.3390/ijerph182212099.Int J Environ Res Public Health. 2021.PMID:34831853Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials